Author Archives: Scalper1

Pharma ETFs To Buy On String Of Q3 Earnings Beats

Like in the past few quarters, the healthcare sector continued to impress with its earnings in Q3. This is especially true as total earnings for 78.8% of the sector’s total market capitalization are up 12.5% on revenue growth of 8.4%, with earnings and revenue beat ratios of 83.3% and 61.1%, respectively. In fact, the sector is leading the way higher in terms of beating revenue estimates, where the overall growth picture of the S&P 500 is lagging. Among the most notable players, Johnson & Johnson (NYSE: JNJ ) was the first major drug company to report earnings on October 13, followed by Eli Lilly and Company (NYSE: LL ) on October 22. The other three major U.S. drug companies – Pfizer (NYSE: PFE ), Merck (NYSE: MRK ) and Bristol-Myers Squibb Company (NYSE: BMY ) – reported on October 27. All these industry primes outpaced our earnings estimates as well as raised their full-year outlook, while some missed on the revenue front. Johnson & Johnson’s Earnings in Focus The world’s biggest maker of healthcare products continued its long streak of earnings beats despite currency headwinds, which were responsible for the revenues missing our estimates. Earnings per share came in at $1.49, a nickel above the Zacks Consensus Estimate, but 7.4% lower than the year-ago earnings. Revenues slid 7.4% year over year to $17.1 billion and fell shy of the Zacks Consensus Estimate of $17.4 billion. In spite of the fact that a strong U.S. dollar would remain a major drag on international revenue growth, the company raised the lower end of the earnings per share guidance range to $6.15-6.20 from $6.10-6.20. The new midpoint is above the Zacks Consensus Estimate of $6.16 at the time of revising the guidance, reflecting confidence in its future growth. JNJ has gained 6.4% to-date since its earnings announcement. Pfizer’s Earnings in Focus The U.S. drug giant topped the Zacks Consensus Estimate for the top and the bottom lines, and raised its guidance for the fiscal 2015. Earnings per share of 60 cents and revenues of $12.01 billion were ahead of our estimates by a nine cents and $0.65 billion, respectively. Notably, earnings per share rose 5%, while revenues slid 2% year over year. Based on the earnings beat, Pfizer raised its revenue and earnings outlook for fiscal 2015. The company now expects earnings per share of $2.16-2.20 and revenues of $47.5-48.5 billion, compared to the previous outlook of $2.04-2.10 and $46.5-47.5 billion, respectively. The Zacks Consensus Estimate was $2.09 for earnings and $47.7 billion for revenues at the time of revising the guidance. Shares of PFE have moved up 2.6% since the earnings announcement. Merck’s Earnings in Focus Merck’s earnings per share came in at 96 cents, a nickel ahead of the Zacks Consensus Estimate and 6.7% higher than the year-ago earnings. Revenues slipped 4.6% year over year to $10.07 billion, and were slightly below the Zacks Consensus Estimate of $10.09 billion. For fiscal 2015, Merck raised the low end of the revenue guidance to $39.2-39.8 billion from $38.6-39.8 billion, including currency headwinds of $1 billion, and boosted the earnings per share outlook to $3.55-3.60 from $3.45-3.55. The Zacks Consensus Estimate at the time of the earnings release was pegged at $3.50 for earnings and $39.6 billion for revenues. The stock has added about 4.1% to-date post its earnings announcement. Bristol-Myers’ Earnings in Focus Bristol-Myers reported earnings per share of 39 cents, outpacing our estimate by four cents, but declining 13% from the year-ago earnings. Meanwhile, revenues climbed 4% to $4.07 billion and edged past the Zacks Consensus Estimate of $3.85 billion. Like the other drug makers, the company raised its full-year earnings per share guidance range to $1.85-1.90 from $1.70-$1.80, the midpoint of which was lower than our estimate of $1.82 at the time of the earnings announcement. Revenues are expected at $16.0-16.4 billion, which is at the low end of the Zacks Consensus Estimate of $16 billion. Shares of BMY are up 1.8% to-date since the earnings announcement. Eli Lilly’s Earnings in Focus Earnings of 89 cents at Eli Lilly strongly beat the Zacks Consensus Estimate by 13 cents and came in 22% higher than the year-ago earnings. Revenues slid 4% to $4.960 billion, and were marginally below our estimate of $4.962 billion. Eli Lilly also boosted its full-year outlook, with earnings per share revised upward from $3.20-3.30 to $3.40-3.45. Meanwhile, the company maintained its revenue guidance of $19.7-20.0 billion. The Zacks Consensus Estimate at the time of the earnings release was pegged at $3.27 per share for earnings and $19.9 billion for revenues. Shares of LLY have climbed 6.5% since the earnings announcement. ETF Angle The string of earnings beats and raised outlook has driven pharma ETFs higher from a one-month look. This trend is likely to continue for the rest of the year, given that the industry has a robust Zacks Industry Rank in the top 25% at the time of writing. Further, all these funds have a solid Zacks ETF Rank of 1 (Strong Buy) or 2 or (Buy), suggesting their continued outperformance (see all the Healthcare ETFs here ). iShares U.S. Pharmaceuticals ETF (NYSEARCA: IHE ) This ETF provides exposure to 43 pharma stocks by tracking the Dow Jones U.S. Select Pharmaceuticals Index. The five in-focus firms are among the top six holdings, accounting for 42.6% of total assets, suggesting heavy concentration. The product has $891.8 million in AUM and charges 43 bps in fees and expense. Volume is light, as the fund exchanges about 67,000 shares a day. IHE added about 6.9% over the past one month. PowerShares Dynamic Pharmaceuticals Portfolio ETF (NYSEARCA: PJP ) This is by far the most popular choice in the pharma space that follows the Dynamic Pharmaceuticals Intellidex Index. The product has AUM of about $1.6 billion, and sees good volume of around 233,000 shares a day. The fund charges 56 bps in fees and expenses from investors. Holding 23 stocks, PJP invests more than one-fourth of its assets in the in-focus five firms. The ETF surged about 8% over the trailing one-month period. Market Vectors Pharmaceutical ETF (NYSEARCA: PPH ) This ETF follows the Market Vectors US Listed Pharmaceutical 25 Index and holds 26 stocks in its basket. JNJ, PFE, MRK, LLY and BMY are among the top 12 holdings that make up for a combined 28.9% share. The product has amassed $338.6 million in its asset base, and trades in a moderate volume of about 72,000 shares a day. The expense ratio came in at 0.35%. The fund was up about 4% over the past one-month period. SPDR S&P Pharmaceuticals ETF (NYSEARCA: XPH ) This fund provides an almost equal-weight exposure to the pharma companies by tracking the S&P Pharmaceuticals Select Industry Index. With AUM of over $719.6 million, it trades in moderate volume of around 72,000 shares a day and charges 35 bps in fees a year. In total, the product holds 43 securities, with the in-focus five firms taking nearly 3% share each. The product has added 7.2% in the same period. Original Post

Maximizing Shareholder Value: A Dumb Idea?

Sometime in 2007, I called the Investor Relations head of a leading Indian power company. “I request for a meeting with your CFO,” I said. “Where are you calling from?” she asked back. “I work for an independent research company working for retail investors, and we are looking to initiate coverage on your stock,” I replied. “I had some questions before writing the report, and thus wanted to meet your CFO.” “Are you writing a Buy or a Sell report on our stock?” she asked. “How can I tell you that now?” I said. “I need to finish my research, and only then will I make a judgement on whether the stock is a Buy or a Sell.” “Wait, you are from a retail research organization, right?” she asked. “Sorry, we do not have a policy to meet companies focused on retail investors. We only meet the institutional guys because they can help up increase our market cap, not the retail guys. We want to maximize shareholders’ wealth, you see.” I loved her honesty, but was shocked to hear such a response from a public company, which had a policy of maximizing shareholder wealth, and fast, and by excluding a large set of its shareholders. What a Dumb Idea! Peter Drucker said in 1973: The only valid purpose of a firm is to create a customer. Drucker’s perspective was that the goal of a firm isn’t fundamentally about creating profits or maximizing shareholder value. Profits and shareholder value are the results of adding value to customers, not the goal. Even the legendary Jack Welch has come to see that maximizing shareholder value is “the dumbest idea in the world.” “On the face of it, shareholder value is the dumbest idea in the world,” Welch said, “Shareholder value is a result, not a strategy…your main constituencies are your employees, your customers and your products.” Seth Godin wrote in a recent post – The purpose of a company is to serve its customers. Its obligation is to not harm everyone else. And its opportunity is to enrich the lives of its employees. Somewhere along the way, people got the idea that maximizing investor return was the point. It shouldn’t be. That’s not what democracies ought to seek in chartering corporations to participate in our society. The great corporations of a generation ago, the ones that built key elements of our culture, were run by individuals who had more on their mind than driving the value of their options up. Contrast this with what most companies and their managers do, i.e., focus on short-term profits and stock price maximization, because this is an easy thing to do. Look at what the DCB Bank did recently. Some days back, the management announced that the bank’s profits would take a knock as it tries to double its branch network in the next one year. On this news, the stock price crashed 30% in quick time. Shattered by this crash in the stock, the management revised its plan saying that, “after consultations with analysts and its chairman,” it would now not rush with the opening of new branches. Instead of setting up 150 branches over the next one year, it will do this over two years. While I have no view on the bank or how this branch expansion would have helped or hurt it, the questions that arise are: How can a management change its corporate plan while keeping an eye on the stock price? How on earth can you consult stock market analysts on what you want to do as corporate managers? The answer, again, seems to be – focus on short-term profit and stock price maximization versus long-term goals. All CEOs and corporate managers appearing on business channels talking about their profits and next quarter’s or year’s performance are focused on just that – maximizing their company’s stock prices in the short term. Companies that never organize analyst meets or conference calls and become active when their stock price is rising are also focused on that – further maximizing their stock prices in the short term. Companies that pay dividends out of borrowed money are also doing the same. Steve Denning wrote this in his 2011 article on Forbes: CEOs and their top managers have massive incentives to focus most of their attentions on the expectations market, rather than the real job of running the company producing real products and services. The real market is the world in which factories are built, products are designed and produced, real products and services are bought and sold, revenues are earned, expenses are paid, and real dollars of profit show up on the bottom line. That is the world that executives control-at least to some extent. The expectations market is the world in which shares in companies are traded between investors-in other words, the stock market. In this market, investors assess the real market activities of a company today and, on the basis of that assessment, form expectations as to how the company is likely to perform in the future. The consensus view of all investors and potential investors as to expectations of future performance shapes the stock price of the company. Roger Martin wrote this in his book ” Fixing the Game “: What would lead [a CEO] to do the hard, long-term work of substantially improving real-market performance when she can choose to work on simply raising expectations instead? Even if she has a performance bonus tied to real-market metrics, the size of that bonus now typically pales in comparison with the size of her stock-based incentives. Expectations are where the money is. And of course, improving real-market performance is the hardest and slowest way to increase expectations from the existing level. Invest with People Focused on Customers, Not Stock Prices The problem with short-term stock price maximization is that it’s not particularly difficult. If a company has a big market share, or if it’s difficult for the customer to switch away from the company’s product, or if the customer lacks the knowledge of better options, it’s easy for the company to hurt its customers on the way to boosting what the shareholders say they want. So, it’s not difficult for Nestle ( OTCPK:NSRGY , OTCPK:NSRGF ) to be casual about what its super-branded food products contain (thanks to its large market share), or for Indian Railways to provide sub-standard travel experience (customers don’t easily switch), or for financial services companies to mis-sell bad products (customers lack knowledge about good products). But just because it works doesn’t mean that they should be doing it to maximize short-term profits, and in many cases, their stock prices. Contrast this with what Jeff Bezos and Larry Page are doing at Amazon (NASDAQ: AMZN ) and Alphabet ( GOOG , GOOGL ) respectively – focusing only, and only, on the customer. The reason they have created so much wealth for their shareholders is because they never cared about shareholder value maximization, but only about customer satisfaction. Consider the Purpose Statement of Procter & Gamble (NYSE: PG ) (emphasis mine) : We will provide branded products and services of superior quality and value that improve the lives of the world’s consumers, now and for generations to come. As a result , consumers will reward us with leadership sales, profit and value creation, allowing our people, our shareholders and the communities in which we live and work to prosper. For P&G, consumers come first and shareholder value naturally follows. As per the statement of purpose, if P&G gets things right for consumers, shareholders will be rewarded as a result. This, I am sure, has also been the mantra of India’s biggest long-term wealth creators like HDFC (NYSE: HDB ), Asian Paints ( OTC:ASNQY ), Sun Pharma ( OTC:SMPQY ), Infosys (NYSE: INFY ), and Wipro (NYSE: WIT ). They have created tremendous shareholder wealth as a result of their focus on their customers and building their business for the long term, and not the other way round. This is how you can also find a few of the future wealth creators – businesses where managements are not focused on shareholder wealth creation, but treat it just as a byproduct of delighting its customers, employees, and the society at large. Such are the businesses where you will find long-term sustainable moats. Every other moat – especially if it appears a lot on business television, is worshipped by everyone around, and where the management often touts its shareholder-friendliness – is often fleeting. “Mr. Market suffers from incurable emotional problems,” Ben Graham wrote while describing the daily madness of stock price movements. Why would you want to partner with business managers who focus on managing these incurable problems of Mr. Market, rather than minding their business?